- Home
- INM vs FCNCO Comparison
INM vs FCNCO Comparison
Compare INM & FCNCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INM | FCNCO |
|---|---|---|
| Founded | 1981 | 1898 |
| Country | Canada | United States |
| Employees | N/A | 18141 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | N/A |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | INM | FCNCO |
|---|---|---|
| Price | $0.80 | $21.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.8K | 12.7K |
| Earning Date | 05-11-2026 | 10-23-2025 |
| Dividend Yield | N/A | ★ 6.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 169.27 |
| Revenue | $4,942,633.00 | ★ $8,897,000,000.00 |
| Revenue This Year | N/A | $0.56 |
| Revenue Next Year | N/A | $2.24 |
| P/E Ratio | ★ N/A | $0.13 |
| Revenue Growth | ★ 7.50 | N/A |
| 52 Week Low | $0.73 | $20.57 |
| 52 Week High | $7.98 | $23.91 |
Technical Indicators
Market Signals| Indicator | INM | FCNCO |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 25.67 |
| Support Level | $0.73 | $21.25 |
| Resistance Level | $0.95 | $22.78 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 28.74 | 2.84 |
Price Performance
Historical ComparisonAbout INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
About FCNCO First Citizens BancShares Inc. 5.625% Non-Cumulative Perpetual Preferred Stock Series C
First Citizens BancShares Inc. is a Raleigh, N.C.-based financial holding company operating through its subsidiary, First-Citizens Bank & Trust Company. It provides comprehensive retail banking, commercial lending, leasing, and wealth management services via a nationwide branch network and digital platforms. In 2023 acquisition of Silicon Valley Bank, it also specializes in banking for tech, healthcare, and innovation firms.